-
May 3, 2024 Lupin Launches Rymti® Biosimilar Etanercept in Canada
-
April 25, 2024 Lupin Receives Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Suspension, 0.5%
-
April 25, 2024 Lupin Digital Health’s Lyfe Platform Receives Class C Medical Device License from CDSCO
-
April 23, 2024 Lupin Receives EIR from U.S. FDA for its Aurangabad Manufacturing Facility
-
April 22, 2024 Lupin Launches Mirabegron Extended-Release Tablets in the United States
-
April 12, 2024 U.S. FDA Completes Inspection of Lupin’s Dabhasa Facility with No Observations
-
April 9, 2024 Lupin Launches First Generic Version of Oracea® (Doxycycline Capsules) in the United States
-
April 8, 2024 Lupin Receives Approval from U.S. FDA for Valbenazine Capsules
-
April 3, 2024 Lupin Appoints Dr. Ranjana Pathak as Chief Quality Officer